Drug intelligence / Profile preview

influenza hemagglutinin mRNA vaccine

Development stage: Approved
Lead developer: Sanofi Pasteur
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The influenza hemagglutinin mRNA vaccine is a messenger ribonucleic acid (mRNA) vaccine designed to induce an immune response against the influenza virus. It works by delivering mRNA that encodes for influenza hemagglutinin, a key viral surface protein. Upon administration, the host cells translate this mRNA into the hemagglutinin protein, which is then presented to the immune system, triggering the production of antibodies and cellular immunity to protect against influenza infection. This vaccine is being developed by Sanofi Pasteur.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on influenza hemagglutinin mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza hemagglutinin mRNA vaccine.

Explore the full profile